Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Pharmaceuticals
- Therapeutic
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26723
License Grant
The contract was entered with a privately held British company and provides for worldwide distribution rights so long as there are existing patents and the parties continue their corporate existence.
License Property
NEBO 224 involves stem cell research and intended biological products or processes for the treatment of arthritis. The product is developed pursuant to a joint licensing and development agreement with a private Gibraltar based British company.
IPSCIO Record ID: 26495
License Grant
The contract provides for worldwide distribution rights with a privately held British company for so long as there are patents and there is a continued corporate existence of the parties.
License Property
NEBO 178 is a development stage process using stem cell technology to develop biological compounds for the intended treatment of Alzheimers Disease and related neurological disorders.
The treatment process relies upon basic stem cell research to develop anticipated biological products for treatment of this disease or related neurological disorders. The product is being developed in a joint development and marketing agreement with a privately held British corporation.
Field of Use
The rights granted relate to neurological disorders, i.e. Alzheimers.
IPSCIO Record ID: 26493
License Grant
The Licensor a privately held British company and the Licensee have entered into an agreement which provides for the joint development and marketing of this product on a worldwide basis as long as the patent rights exist and the parties to the agreement continue.
License Property
NEBO 176 is a biological process based upon stem cell research to develop naturally occurring biological compounds for the treatment of Parkinsons Disease and related neurological disorders.
IPSCIO Record ID: 26813
License Grant
NEBO 174 is a drug proposed with a privately held British company for the treatment of depression and related symptoms as licensed from a private British based company. The product is to be marketed under the proposed trade name of Nivazole on a worldwide basis.
Field of Use
The field of use relates to the pharmaceutical market in the healthcare industry.
IPSCIO Record ID: 26724
License Grant
This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.
License Property
BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms. The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.
Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.
Field of Use
The rights granted relate to neurological symptoms.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
